Wang Xiaodong, a director and Chair of the Scientific Advisory Board at BeiGene (NASDAQ:ONC), Ltd. (NASDAQ:BGNE), recently sold shares worth approximately $7.37 million, according to a recent SEC filing. The transactions, which took place on January 7, involved the sale of American Depositary Shares at prices ranging from $175.46 to $179.18. According to InvestingPro analysis, BeiGene is currently trading near its 52-week high, with the stock showing signs of being slightly overvalued based on Fair Value metrics.
In addition to the sales, Wang exercised options to acquire 542,880 shares at a price of $6.50 per share, amounting to a total value of $271,440. Following these transactions, Wang holds a significant number of shares both directly and indirectly, through various trusts and entities. InvestingPro data reveals BeiGene’s impressive revenue growth forecast of 56% for FY2025, suggesting strong future potential despite current market positioning.
The sales were conducted under a Rule 10b5-1 trading plan, which was adopted on August 12, 2024. Each American Depositary Share sold represents 13 ordinary shares of BeiGene. Get deeper insights into BeiGene’s financial health metrics and more exclusive analysis with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.